EPM2A antibody (AA 243-331)

Catalog No. ABIN336090

Product Details anti-EPM2A Antibody

Target: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Binding Specificity: AA 243-331

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This EPM2A antibody is un-conjugated

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Specificity: The antibody recognizes EPM2A.

Cross-Reactivity (Details): Species reactivity (tested):Human

Characteristics: Synonyms: EPM2A, Laforin, EC=3.1.3.48, EC=3.1.3.16, Lafora PTPase, LAFPTPase

Purification: Protein-G affinity chromatography

Immunogen: Recombinant human EPM2A (aa 243-331) purified from E. coli

Clone: K2A3

Isotype: IgG1

Application Details

Application Notes: ELISA. Western blot (1: 1,000 - 1: 2,000).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.0 mg/mL

Buffer: PBS, pH 7.4, containing 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for up to two weeks or (in aliquots) at -20 °C forlonger. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

Expiry Date: 12 months

Target Details for EPM2A

Target: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Alternative Name: Laforin (EPM2A Products)

Synonyms: TG-B antibody, Tg(TcraK,TcrbK)TG-BFlv antibody, EPM2 antibody, MELF antibody, laforin antibody, EPM2A, laforin glucan phosphatase antibody, epilepsy, progressive myoclonic epilepsy, type 2 gene alpha antibody, EPM2A antibody, Epm2a antibody

Background: Epilepsy, progressive myoclonus type 2A (EPM2A), also known as laforin, is a dual-specificity phosphatase that associates with polyribosomes. The protein may be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules. Defects in EPM2A are a cause of progressive myoclonic epilepsy type 2(EPM2), also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy.Synonyms: EC=3.1.3.16, EC=3.1.3.48, EPM2A, LAFPTPase, Lafora PTPase, Laforin

Gene ID: 7957

UniProt: O95278

Pathways: Cellular Glucan Metabolic Process